Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline

Two preclinical programs developed by Canadian biotech Northern Biologics have been acquired by privately held German company Boehringer Ingelheim, which is looking to bolster its cancer immunology portfolio.